Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (121-130 of 155) with videos related to

Pageof 16
Sort By:
The Oncologist|April 22, 2025
Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomesYasaman Iranmanesh, Noha Omar, Arya Rasouli, et al.
The Journal of Clinical Investigation|July 17, 2019
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damagePayel Chatterjee, Michael T Schweizer, Jared M Lucas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2024
Initial Experience with [<sup>177</sup>Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome PredictionAndrei Gafita, Andrew Voter, Somya Shesadri, et al.
Nature Reviews. Urology|November 1, 2023
Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancerJoakin O Mori, Isra Elhussin, W Nathaniel Brennen, et al.
European Urology|July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide CohortsMark C Markowski, Hao Wang, Rana Sullivan, et al.
Biomaterials|March 29, 2016
A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancerOren Levy, W Nathaniel Brennen, Edward Han, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2020
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapyLaura A Sena, Hao Wang, Su J Lim ScM, et al.
Oncogene|May 7, 2021
Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitorsYezi Zhu, Susan L Dalrymple, Ilsa Coleman, et al.
Oncogene|September 29, 2020
Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitorsYezi Zhu, Susan L Dalrymple, Ilsa Coleman, et al.
Oncogene|February 10, 2021
Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitorsYezi Zhu, Susan L Dalrymple, Ilsa Coleman, et al.
Pageof 16

Showing results (121-130 of 155) with videos related to

Sort By:
Pageof 16
The Oncologist|April 22, 2025
Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomesYasaman Iranmanesh, Noha Omar, Arya Rasouli, et al.
The Journal of Clinical Investigation|July 17, 2019
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damagePayel Chatterjee, Michael T Schweizer, Jared M Lucas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2024
Initial Experience with [<sup>177</sup>Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome PredictionAndrei Gafita, Andrew Voter, Somya Shesadri, et al.
Nature Reviews. Urology|November 1, 2023
Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancerJoakin O Mori, Isra Elhussin, W Nathaniel Brennen, et al.
European Urology|July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide CohortsMark C Markowski, Hao Wang, Rana Sullivan, et al.
Biomaterials|March 29, 2016
A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancerOren Levy, W Nathaniel Brennen, Edward Han, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2020
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapyLaura A Sena, Hao Wang, Su J Lim ScM, et al.
Oncogene|May 7, 2021
Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitorsYezi Zhu, Susan L Dalrymple, Ilsa Coleman, et al.
Oncogene|September 29, 2020
Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitorsYezi Zhu, Susan L Dalrymple, Ilsa Coleman, et al.
Oncogene|February 10, 2021
Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitorsYezi Zhu, Susan L Dalrymple, Ilsa Coleman, et al.
Pageof 16